Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/03/18	$58,500,000	Series A	Third Rock Ventures	undisclosed
09/10/20	$50,000,000	Series B	Eventide Asset Management Schroder Adveq The Column Group Third Rock Ventures	undisclosed
11/15/22	$46,000,000	Series C	Amgen Ventures Astellas Venture Management Eisai Euclidean Capital Eventide Asset Management Mirae Asset Capital Ono Venture Investment Schroders Capital The Column Group Third Rock Ventures	undisclosed